EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA
- $ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC
- PROCEEDS TO ACCELERATE SCALING AS LEADING AI DRUG DISCOVERY COMPANY
Hamburg, Germany, 07 January 2019: Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today an additional investment of approximately $ 6 m towards Exscientia's latest funding round (Series B). Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, has raised $ 26 m in a Series B financing round. Celgene Corporation and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.
The company will use the proceeds of this financing round to grow its "full stack" AI drug discovery capability and to expand its pipeline, with a target of establishing an expansive portfolio of projects, both in-house and with partners.
"Exscientia and Evotec have been partners since early 2016 to advance novel small molecules and bispecific small molecules in immuno-oncology. The excellent progress of this partnership, and the great recent industry validations of our initial investment, are the basis of the expanded and deepened corporate relationship and investment," said Dr Werner Lanthaler, Chief Executive Officer of Evotec.
Professor Andrew Hopkins, CEO and founder of Exscientia, commented: "This Series B marks a milestone in our development and enables us to drive the next phase of strong business growth. Over the past 12 months, we have substantially expanded our operations and capabilities to become a full stack AI drug discovery company. Furthermore, our unique Centaur Chemist(TM) platform allows us to move rapidly from idea generation to new drug molecules ready for IND and clinical development. With this new funding, Exscientia is positioned to become the dominant player in AI drug discovery, driving radical change in R&D productivity."
Dr Craig Johnstone, Chief Operating Officer of Evotec added: "We are very pleased to continue to participate in the growth of Exscientia. This investment is another indicator of our commitment to the development of cutting-edge technologies, including the application of machine learning and artificial intelligence to improve predictive power in drug discovery science."
Exscientia has made considerable progress during 2018 and anticipates its first IND-ready programmes, driven by AI, in the next 12 months.
ABOUT EXSCIENTIA
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. Exscientia's innovative Centaur Chemist(TM) platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Roche and Evotec.
Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan.
For more information visit www.exscientia.co.uk or follow us on Twitter @exscientialtd
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter@EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com